Table 1. Ongoing studies.
| Study | Indication | Study design | Treatment arm | Primary endpoint | Anticipated completion |
|---|---|---|---|---|---|
| SIRveNIB (NCT01135056) | HCC (intermediate—advanced) | RCT multicenter | Sorafenib | Survival | Not available |
| SIR Spheres | |||||
| SARAH (NCT01482442) | HCC (advanced) | RCT multicenter | Sorafenib | Survival | By early 2017 |
| SIR Spheres | |||||
| SORAMIC (NCT01126645) | HCC (early-advanced) | RCT multicenter | Sorafenib | Survival | Early 2018 |
| SIR Spheres > sorafenib | |||||
| STOCS (NCT02167711) | ICC (advanced) | Single arm, multicenter | SIR Spheres > | Survival | Late 2016 |
| Gemcitabine + cisplatin | |||||
| SIRT-TACE-CCC (NCT01798147) | ICC (advanced) | RCT single-center | TACE | PFS | Late 2016 |
| SIR Spheres |
Sources: http://www.sirtex.com/media/35508/clinical-investigation-programme-964-ea-0115.pdf; www.clinicaltrials.gov. HCC, hepatocellular carcinoma.